No description available.

Background: Inflammatory bowel disease (IBD) is an umbrella term for ulcerative colitis and Crohn's disease. These are characterized by a chronic inflammation of the intestinal mucosa. Living with chronic illness meant that life changed significantly. Quality of life was affected for these individuals and was stressful in their lives.   Aim: The aim was to describe the experiences of living with inflammatory bowel disease.   Method: A qualitative literature review was chosen to analyze articles that were related to the aim of this study.   Results: Based on the chosen articles five themes were created; Commuting between hope and fear, symptoms of the disease and medication become everyday focus, struggling with  the new identity, desire to control the disease- do I control my illness or does it control me and social relationships are affected.   Conclusion: Inflammatory bowel disease is a distressing disease and can cause limitations in social life due to lack of knowledge by others about the disease. The affected felt a loss of control in their life due to the difficulty in managing the symptoms. They experienced a constant struggle and mixed emotions, such as anxiety, depression, stress, and denial of the disease, trying to feel like a healthy person.

O nosso objetivo foi mensurar os níveis de Interleucina-6 (IL-6) no fluido gengival de pacientes com periodontite e doença inflamatória intestinal (DII), comparando-os com pacientes sistemicamente saudáveis, com periodontite. Como objetivo secundário será avaliada a IL-6 no soro desses pacientes. Foram selecionados 15 pacientes com doença de Crohn (DC, idade média 38.2, DP 11.4 anos), 15 com retrocolite ulcerativa idiopática (RCUI, 45.0 10.5 anos) e 15 pacientes saudáveis (C, 42.1 7.8 anos). A Profundidade de bolsa (PB), nível de inserção clínica (NI), presença de placa e de sangramento a sondagem foram avaliados em seis sítios por dente. O fluido gengival foi coletado de quatro sítios com periodontite (PP: PB ≥ 5mm, NI ≥ 3mm) e quatro sítios com gengivite (GP: PB ≤ 3mm e NI≤ 1mm), em dentes diferentes, com pontas de papel absorvente pré-fabricadas. O soro destes pacientes também foi coletado. A análise da IL-6 foi realizada pelo LUMINEX. A quantidade total e concentração da IL-6 estavam significantemente maiores no fluido gengival dos sítios PP do grupo RCUI quando comparados aos sítios PP do grupo controle (p=0.028; p=0.044, respectivamente). O grupo DC apresentou a quantidade total de IL-6 significantemente maior no sítio PP do que no GP (p=0.028). Já no soro, a IL-6 não diferiu entre os grupos. Sendo assim, pode-se concluir que os indivíduos com retrocolite ulcerativa idiopática apresentavam níveis mais altos de IL-6 nos sítios com periodontite, o que pode indicar um importante papel dessa citocina no estabelecimento e progressão da doença periodontal nesses pacientes. / Our aim was to measure the levels of interleukin-6 in gingival crevicular fluid (GCF) from patients with periodontitis and inflammatory bowel disease (IBD), and compare with systemically healthy controls with periodontitis. Besides, was measured IL-6 level in serum. Fifteen patients with Crohns disease (CD, mean age 38.2 11.4 years), 15 with ulcerative colitis (RCUI, 45.0 10.5) and 15 controls (C, 42.1 7.8) participated in this study. Probing pocket depth (PPD), attachment loss (CAL), presence of plaque and presence of bleeding on probing, were assessed in six sites per tooth. In each subject, GCF from four sites with gingivitis (GP- PPD≤ 3mm and CAL ≤ 1mm) and from 4 sites with periodontitis (PP- PPD ≥ 5mm and CAL ≥ 3mm), on different teeth, were collected with filter strips. The serum of those patients was also collected. The IL-6 was analyzed in the Luminex. The total amount and the concentration of IL-6 in GCF was significantly higher in PP sites from RCUI than in controls (p=0.028 e p=0.044, respectively). The total amount of IL-6 was significantly higher in PP than GP sites in the DC group (p=0.028). In serum, IL-6 does not differ between groups. Therefore was concluded that subjects with ulcerative colitis showed higher levels of IL-6 in periodontitis sites, which might indicate an important role of this cytokine in the onset and progression of periodontal disease in such patients.

O nosso objetivo foi mensurar os níveis de Interleucina-6 (IL-6) no fluido gengival de pacientes com periodontite e doença inflamatória intestinal (DII), comparando-os com pacientes sistemicamente saudáveis, com periodontite. Como objetivo secundário será avaliada a IL-6 no soro desses pacientes. Foram selecionados 15 pacientes com doença de Crohn (DC, idade média 38.2, DP 11.4 anos), 15 com retrocolite ulcerativa idiopática (RCUI, 45.0 10.5 anos) e 15 pacientes saudáveis (C, 42.1 7.8 anos). A Profundidade de bolsa (PB), nível de inserção clínica (NI), presença de placa e de sangramento a sondagem foram avaliados em seis sítios por dente. O fluido gengival foi coletado de quatro sítios com periodontite (PP: PB ≥ 5mm, NI ≥ 3mm) e quatro sítios com gengivite (GP: PB ≤ 3mm e NI≤ 1mm), em dentes diferentes, com pontas de papel absorvente pré-fabricadas. O soro destes pacientes também foi coletado. A análise da IL-6 foi realizada pelo LUMINEX. A quantidade total e concentração da IL-6 estavam significantemente maiores no fluido gengival dos sítios PP do grupo RCUI quando comparados aos sítios PP do grupo controle (p=0.028; p=0.044, respectivamente). O grupo DC apresentou a quantidade total de IL-6 significantemente maior no sítio PP do que no GP (p=0.028). Já no soro, a IL-6 não diferiu entre os grupos. Sendo assim, pode-se concluir que os indivíduos com retrocolite ulcerativa idiopática apresentavam níveis mais altos de IL-6 nos sítios com periodontite, o que pode indicar um importante papel dessa citocina no estabelecimento e progressão da doença periodontal nesses pacientes. / Our aim was to measure the levels of interleukin-6 in gingival crevicular fluid (GCF) from patients with periodontitis and inflammatory bowel disease (IBD), and compare with systemically healthy controls with periodontitis. Besides, was measured IL-6 level in serum. Fifteen patients with Crohns disease (CD, mean age 38.2 11.4 years), 15 with ulcerative colitis (RCUI, 45.0 10.5) and 15 controls (C, 42.1 7.8) participated in this study. Probing pocket depth (PPD), attachment loss (CAL), presence of plaque and presence of bleeding on probing, were assessed in six sites per tooth. In each subject, GCF from four sites with gingivitis (GP- PPD≤ 3mm and CAL ≤ 1mm) and from 4 sites with periodontitis (PP- PPD ≥ 5mm and CAL ≥ 3mm), on different teeth, were collected with filter strips. The serum of those patients was also collected. The IL-6 was analyzed in the Luminex. The total amount and the concentration of IL-6 in GCF was significantly higher in PP sites from RCUI than in controls (p=0.028 e p=0.044, respectively). The total amount of IL-6 was significantly higher in PP than GP sites in the DC group (p=0.028). In serum, IL-6 does not differ between groups. Therefore was concluded that subjects with ulcerative colitis showed higher levels of IL-6 in periodontitis sites, which might indicate an important role of this cytokine in the onset and progression of periodontal disease in such patients.

Introduction: Inflammatory bowel disease (IBD), Crohn’s Disease and ulcerative colitis, are long term conditions which follow a relapsing and remitting pattern. The rising incidence of IBD in adults and children has implications for the lifelong burden of disease and the provision of specialist services. Patients are predominantly managed by secondary care and follow a traditional, scheduled follow-up cycle, which is unsustainable and unsatisfactory. Patients with IBD should have access to specialist care which is delivered according to their values and needs. However few studies have examined patients’ views of follow-up care. There is also concern in the UK that services for patients with long term conditions are not orgnised to promote independence with silo working in primary and secondary care.These may be brought together formally through the development of models of care. Utilization of current out-patient spaces to regularly review stable patients is inappropriate and is challenged by commissioners. The question remains as to what models of follow-up are we able to offer patients which are acceptable and what is the role of the general practitioner (GP) and primary care within this. The aim of this study was to develop an integrated, acceptable, model of follow-up care for patients with IBD.Methods The study follows the development phase of the MRC Framework for complex interventions. A best evidence synthesis was undertaken to identify the follow-up care models in IBD. A meta-synthesis of the health and social care needs of patients with IBD was conducted to explore the impact of living with IBD. Qualitative interviews with 24 IBD patients (18 patients had CD, and 6 UC, age range 27-72 years, disease duration range 2 – 40yr) and 20 GPs purposively selected from across NW England were carried out. Patients were asked about their experience, values and preference of follow-up care. The GPs were questioned about their current and potential role in IBD. Analysis was undertaken using Framework Analysis. The best evidence synthesis, meta-synthesis and interviews were synthesised by an expert panel, Consultant Gastroenterologist, patient, GP, IBD Nurse, to develop the model of follow-up care.Results There were similarities and commonalities between the patient and general practitioner interviews. Patients did not want to be seen when well, GPs wanted more involvement in care and there is scope for an IBD outreach nurse at the interface of primary/secondary care. Discharging quiescent patients into enhanced GP care, to ensure equitable treatment, was acceptable to all, as was the concept of ‘virtual’ clinics. Patients would initiate self referral within the ‘virtual’ arm whilst patients under GP care would be referred back into secondary care as a rapid referral < 7days and not using a new patient tariff. Complex IBD patients would remain under secondary care. A stratified model of follow-up care was developed.Conclusion This study provides an acceptable integrated model of follow-up for patients with IBD. It takes into account the growing incidence of IBD and UK policy to reduce inappropriate follow-up. It emphasises role of self management, the integration of primary and secondary care, placing the patient closer to home whilst allowing secondary care to concentrate on complex patient management.

No description available.

No description available.

No description available.

INTRODUÇÃO: O comprometimento pancreático em pacientes com Doença de Crohn (DC) é objeto de poucos estudos, porém as poucas séries sobre o assunto indicam um acometimento de uma parcela significativa dos pacientes, variando de 1,2% a 58%. O ultra-som endoscópico (EUS) apresenta a vantagem de apresentar uma sensibilidade muito maior que o ultra-som abdominal e a tomografia computadorizada. Quando comparado à colangiopancreatografia retrógrada endoscópica, este possui, além de uma maior sensibilidade, um índice de complicações significativamente menor. OBJETIVOS: Avaliar a incidência de alterações pancreáticas ao ultra-som endoscópico em pacientes com Doença de Crohn, correlacionando com fatores clínicos, bioquímicos e endoscópicos. MÉTODOS: Cinqüenta e um pacientes com DC, com idade entre 18 e 60 anos (média de 38 anos), sem história prévia de doença pancreática, diabetes mellitus ou alcoolismo, foram submetidos ao exame de EUS. O grupo controle foi formado por 20 pacientes submetidos ao EUS e que não apresentavam história de doença pancreato-biliar ou de Crohn. Dados clínicos, endoscópicos e laboratoriais foram coletados para posterior correlação. Onze variáveis ecoendoscópicas foram analisadas, tanto ductais quanto parenquimatosas. Os pacientes com três ou mais alterações foram submetidos à colangiorressonância magnética (CRNM). Para análise da função pancreática, foi realizado dosagens de elastase fecal em 39 pacientes. RESULTADOS: Dos pacientes analisados, 56% pertenciam ao sexo feminino, com tempo médio de diagnóstico da enfermidade de 7 anos e índice de atividade da doença (CDAI) médio de 102. Dois pacientes, (3,9%) apresentaram quatro alterações ecoendoscópicas, três pacientes, (5,9%) possuíram três alterações, 11 pacientes, (21,5%) tiveram duas alterações e 13 pacientes, (25,5%) apresentaram apenas uma alteração ao EUS. As alterações parenquimatosas totalizaram 39 achados, contra 11 alterações ductais. Apenas três pacientes (16%) do grupo controle apresentaram uma alteração ecoendoscópica (p<0,001). Os pacientes com três ou mais alterações ao EUS realizaram a CRNM, que não mostrou alterações em nenhum dos casos. Quatro pacientes, (10%) apresentaram dosagens de elastase fecal compatíveis com insuficiência pancreática exócrina, sem apresentar correlação com a ecoendoscopia. O único fator preditivo correlacionado com o número de alterações ao EUS foi doença ileal exclusiva. CONCLUSÕES: Os pacientes com DC possuíram uma alta incidência de anormalidades na morfologia pancreática (aproximadamente 10% com três ou mais alterações no EUS). Estas alterações foram localizadas predominantemente em parênquima, o que pode justificar a falta de correlação com a CRNM / BACKGROUND: Pancreas injury usually is not mentioned as an extra-intestinal manifestation of Crohns disease, but the few available series suggest pancreatic injury in a significant proportion of these patients, ranging from 1.2% to 58% in this series. Endoscopic ultrasound (EUS) presents the advantage of having a much higher sensitivity than the abdominal ultrasound or computadorized tomography in evaluating pancreas abnormalities. Compared to the endoscopic retrograde cholangiopancreatography, EUS has at least an equal sensitivity, with a lower complication rate. AIMS: To evaluate the incidence of pancreatic alterations by means of the EUS in Crohns disease, correlating them with clinical, endoscopic and biochemical data. METHODS: Fifty one patients with Crohns disease, age between 18 and 60 years-old (mean = 38), without previous history of pancreatic disease, diabetes mellitus or alcoholism, were submitted to EUS. The control-group was formed by 20 patients submitted to EUS with no previous history of pancreatic or Crohns disease. Clinical, endoscopic and biochemical data were collected in order to determine possible predictive factors. Eleven variables were analyzed, both in pancreatic parenchyma and ducts. The patients with 3 or more alterations were submitted to magnetic resonance. Pancreatic function was determined using fecal elastase assay in 39 patients. RESULTS: Of the 51 analyzed patients, 56% were female, with mean diagnosis time of seven years (1-25) and Crohns disease Activity Index (CDAI) of 102 (20-419). Two patients (3.9%) presented 4 alterations in the EUS exam, 3 (5.9%) presented 3 alterations, 11 (21.5%) had 2 alterations and 13 (25.5%) had 1 alteration in the EUS, which were statistically significant when compared to the control-group, in whom only 16% presented 1 exam alteration (p<0.001). The parenchymal abnormalities were more common, totalizing 39 findings when compared to 11 ductal abnormalities. The patients with 3 or more alterations in the exam were submitted to magnetic resonance; however, pancreatic lesions were not detected. Four patients (10%) had low fecal elastase measurement, suggestive of exocrine pancreatic insufficiency. None of these patients had significant pancreatic alterations in EUS. The only predictive factor that correlated with the number of alterations in EUS was isolated ileal disease. CONCLUSIONS: Patients with Crohns disease had a higher incidence of pancreatic abnormalities (10% with 3 or more alterations in endoscopic ultrasound) in comparison to the control-group. These alterations were found most frequently in the pancreatic parenchyma, which might explain the lack of correlation with the magnetic resonance, which is more prone to detect duct abnormalities. The only predictive factor to these alterations on EUS was ileal disease

INTRODUÇÃO: O comprometimento pancreático em pacientes com Doença de Crohn (DC) é objeto de poucos estudos, porém as poucas séries sobre o assunto indicam um acometimento de uma parcela significativa dos pacientes, variando de 1,2% a 58%. O ultra-som endoscópico (EUS) apresenta a vantagem de apresentar uma sensibilidade muito maior que o ultra-som abdominal e a tomografia computadorizada. Quando comparado à colangiopancreatografia retrógrada endoscópica, este possui, além de uma maior sensibilidade, um índice de complicações significativamente menor. OBJETIVOS: Avaliar a incidência de alterações pancreáticas ao ultra-som endoscópico em pacientes com Doença de Crohn, correlacionando com fatores clínicos, bioquímicos e endoscópicos. MÉTODOS: Cinqüenta e um pacientes com DC, com idade entre 18 e 60 anos (média de 38 anos), sem história prévia de doença pancreática, diabetes mellitus ou alcoolismo, foram submetidos ao exame de EUS. O grupo controle foi formado por 20 pacientes submetidos ao EUS e que não apresentavam história de doença pancreato-biliar ou de Crohn. Dados clínicos, endoscópicos e laboratoriais foram coletados para posterior correlação. Onze variáveis ecoendoscópicas foram analisadas, tanto ductais quanto parenquimatosas. Os pacientes com três ou mais alterações foram submetidos à colangiorressonância magnética (CRNM). Para análise da função pancreática, foi realizado dosagens de elastase fecal em 39 pacientes. RESULTADOS: Dos pacientes analisados, 56% pertenciam ao sexo feminino, com tempo médio de diagnóstico da enfermidade de 7 anos e índice de atividade da doença (CDAI) médio de 102. Dois pacientes, (3,9%) apresentaram quatro alterações ecoendoscópicas, três pacientes, (5,9%) possuíram três alterações, 11 pacientes, (21,5%) tiveram duas alterações e 13 pacientes, (25,5%) apresentaram apenas uma alteração ao EUS. As alterações parenquimatosas totalizaram 39 achados, contra 11 alterações ductais. Apenas três pacientes (16%) do grupo controle apresentaram uma alteração ecoendoscópica (p<0,001). Os pacientes com três ou mais alterações ao EUS realizaram a CRNM, que não mostrou alterações em nenhum dos casos. Quatro pacientes, (10%) apresentaram dosagens de elastase fecal compatíveis com insuficiência pancreática exócrina, sem apresentar correlação com a ecoendoscopia. O único fator preditivo correlacionado com o número de alterações ao EUS foi doença ileal exclusiva. CONCLUSÕES: Os pacientes com DC possuíram uma alta incidência de anormalidades na morfologia pancreática (aproximadamente 10% com três ou mais alterações no EUS). Estas alterações foram localizadas predominantemente em parênquima, o que pode justificar a falta de correlação com a CRNM / BACKGROUND: Pancreas injury usually is not mentioned as an extra-intestinal manifestation of Crohns disease, but the few available series suggest pancreatic injury in a significant proportion of these patients, ranging from 1.2% to 58% in this series. Endoscopic ultrasound (EUS) presents the advantage of having a much higher sensitivity than the abdominal ultrasound or computadorized tomography in evaluating pancreas abnormalities. Compared to the endoscopic retrograde cholangiopancreatography, EUS has at least an equal sensitivity, with a lower complication rate. AIMS: To evaluate the incidence of pancreatic alterations by means of the EUS in Crohns disease, correlating them with clinical, endoscopic and biochemical data. METHODS: Fifty one patients with Crohns disease, age between 18 and 60 years-old (mean = 38), without previous history of pancreatic disease, diabetes mellitus or alcoholism, were submitted to EUS. The control-group was formed by 20 patients submitted to EUS with no previous history of pancreatic or Crohns disease. Clinical, endoscopic and biochemical data were collected in order to determine possible predictive factors. Eleven variables were analyzed, both in pancreatic parenchyma and ducts. The patients with 3 or more alterations were submitted to magnetic resonance. Pancreatic function was determined using fecal elastase assay in 39 patients. RESULTS: Of the 51 analyzed patients, 56% were female, with mean diagnosis time of seven years (1-25) and Crohns disease Activity Index (CDAI) of 102 (20-419). Two patients (3.9%) presented 4 alterations in the EUS exam, 3 (5.9%) presented 3 alterations, 11 (21.5%) had 2 alterations and 13 (25.5%) had 1 alteration in the EUS, which were statistically significant when compared to the control-group, in whom only 16% presented 1 exam alteration (p<0.001). The parenchymal abnormalities were more common, totalizing 39 findings when compared to 11 ductal abnormalities. The patients with 3 or more alterations in the exam were submitted to magnetic resonance; however, pancreatic lesions were not detected. Four patients (10%) had low fecal elastase measurement, suggestive of exocrine pancreatic insufficiency. None of these patients had significant pancreatic alterations in EUS. The only predictive factor that correlated with the number of alterations in EUS was isolated ileal disease. CONCLUSIONS: Patients with Crohns disease had a higher incidence of pancreatic abnormalities (10% with 3 or more alterations in endoscopic ultrasound) in comparison to the control-group. These alterations were found most frequently in the pancreatic parenchyma, which might explain the lack of correlation with the magnetic resonance, which is more prone to detect duct abnormalities. The only predictive factor to these alterations on EUS was ileal disease